SCD1 Gene

SCD1 Gene

Introduction

Scd1 Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

<nav class="infobox .infobox-gene"> [@dobrzyn2010]
| SCD1 Gene | | [@liu2019]
|---|---| [@flowers2008]
| Full Name | Stearoyl-CoA Desaturase 1 | [@huang2021]
| Symbol | SCD1 | [@zhang2020]
| Chromosome | 10q24.31 | [@nicolini2016]
| NCBI Gene ID | 6319 | [@miyazaki2009]
| OMIM | 604456 | [@konda2021]
| Ensembl ID | ENSG00000197294 | [@zhou2022]
| UniProt | O00767 |
| Associated Diseases | Alzheimer's Disease, Parkinson's Disease, Metabolic Syndrome, Non-Alcoholic Fatty Liver Disease, Cancer |
</nav>

Overview

The SCD1 gene encodes stearoyl-CoA desaturase 1 (SCD1), the rate-limiting enzyme in the synthesis of monounsaturated fatty acids [1]. Located on chromosome 10q24.31, SCD1 catalyzes the introduction of a cis-double bond at the delta-9 position of saturated fatty acids, primarily converting stearoyl-CoA (18:0) to oleoyl-CoA (18:1n-9) [2].

SCD1 is a critical enzyme in lipid metabolism with profound implications for neurodegenerative diseases. The balance between saturated and unsaturated fatty acids is essential for neuronal membrane integrity, synaptic function, and overall brain health. Dysregulation of SCD1 has been implicated in Alzheimer's disease, Parkinson's disease, and various metabolic disorders [3].

Enzyme Structure and Function

Catalytic Mechanism

...

SCD1 Gene

Introduction

Scd1 Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

<nav class="infobox .infobox-gene"> [@dobrzyn2010]
| SCD1 Gene | | [@liu2019]
|---|---| [@flowers2008]
| Full Name | Stearoyl-CoA Desaturase 1 | [@huang2021]
| Symbol | SCD1 | [@zhang2020]
| Chromosome | 10q24.31 | [@nicolini2016]
| NCBI Gene ID | 6319 | [@miyazaki2009]
| OMIM | 604456 | [@konda2021]
| Ensembl ID | ENSG00000197294 | [@zhou2022]
| UniProt | O00767 |
| Associated Diseases | Alzheimer's Disease, Parkinson's Disease, Metabolic Syndrome, Non-Alcoholic Fatty Liver Disease, Cancer |
</nav>

Overview

The SCD1 gene encodes stearoyl-CoA desaturase 1 (SCD1), the rate-limiting enzyme in the synthesis of monounsaturated fatty acids [1]. Located on chromosome 10q24.31, SCD1 catalyzes the introduction of a cis-double bond at the delta-9 position of saturated fatty acids, primarily converting stearoyl-CoA (18:0) to oleoyl-CoA (18:1n-9) [2].

SCD1 is a critical enzyme in lipid metabolism with profound implications for neurodegenerative diseases. The balance between saturated and unsaturated fatty acids is essential for neuronal membrane integrity, synaptic function, and overall brain health. Dysregulation of SCD1 has been implicated in Alzheimer's disease, Parkinson's disease, and various metabolic disorders [3].

Enzyme Structure and Function

Catalytic Mechanism

SCD1 is a member of the stearoyl-CoA desaturase family of enzymes:

• Enzyme type: Membrane-bound desaturase (EC 1.14.19.3)
• Location: Endoplasmic reticulum membrane
• Substrate: Stearoyl-CoA (18:0), palmitoyl-CoA (16:0)
• Product: Oleoyl-CoA (18:1), palmitoleoyl-CoA (16:1)
• Cofactors: Cytochrome b5, NADH, oxygen

Reaction Specificity

| Substrate | Product | Position |
|-----------|---------|----------|
| Stearoyl-CoA (18:0) | Oleoyl-CoA (18:1n-9) | Δ9 |
| Palmitoyl-CoA (16:0) | Palmitoleoyl-CoA (16:1n-7) | Δ9 |

Normal Function in the Brain

Membrane Composition

SCD1-derived monounsaturated fatty acids are essential for [4]:

• Membrane fluidity: Unsaturated fatty acids maintain optimal membrane viscosity
• Lipid raft formation: Cholesterol-rich microdomains require specific lipid composition
• Synaptic function: Presynaptic and postsynaptic membranes need precise lipid balance
• Myelin integrity: Oligodendrocyte membranes depend on appropriate fatty acid ratios

Cellular Processes

In neurons and glia, SCD1 supports:

Lipid droplet formation: Storage of neutral lipids for energy

Protein acylation: Palmitoylation of synaptic proteins

Vesicle trafficking: Membrane fusion events

Mitochondrial function: Inner membrane lipid composition

Metabolic Integration

SCD1 activity integrates with broader metabolic networks:

• Insulin signaling: Lipid composition affects insulin receptor function
• Inflammation: Unsaturated fatty acids modulate inflammatory responses
• Oxidative stress: Membrane susceptibility to peroxidation
• [Autophagy](/entities/autophagy): Lipid metabolism in autophagosome formation

Disease Associations

Alzheimer's Disease [3][5]

SCD1 dysregulation is increasingly recognized in AD:

• Altered desaturation: SCD1 activity changes in AD brain
• Membrane abnormalities: Affects [amyloid precursor protein](/entities/app-protein) (APP) processing
• Lipid raft disruption: Changes in [γ-secretase](/entities/gamma-secretase) localization
• Neuronal vulnerability: Oleic acid protects against [Aβ](/proteins/amyloid-beta) toxicity

| SCD1 Alteration | Effect in AD |
|-----------------|--------------|
| Decreased activity | Increased saturated FA ratio |
| Altered localization | Impaired lipid signaling |
| Interaction with [BACE1](/entities/bace1) | Potential influence on amyloidogenesis |
| Mitochondrial effects | Enhanced oxidative stress |

Parkinson's Disease [6]

SCD1 involvement in PD includes:

• [α-Synuclein](/proteins/alpha-synuclein) interaction: Lipid environments modulate aggregation
• Mitochondrial integrity: Monounsaturated fatty acids for membrane function
• Dopaminergic neuron survival: Lipid homeostasis critical
• Neuroinflammation: SCD1 metabolites modulate glial activation

Metabolic Syndrome [2]

SCD1 is central to metabolic disease:

• Obesity: Hepatic SCD1 overexpression
• Insulin resistance: Altered lipid metabolism
• Fatty liver disease: Triglyceride accumulation
• Dyslipidemia: Altered very-low-density lipoprotein secretion

Cancer

SCD1 is overexpressed in multiple cancers:

• Breast cancer: Associated with poor prognosis
• Prostate cancer: Androgen-regulated expression
• Colorectal cancer: Metabolic reprogramming
• Therapeutic target: SCD1 inhibitors under investigation

Expression Pattern

Brain Regional Distribution

SCD1 shows distinct patterns across brain regions:

• [Hippocampus](/brain-regions/hippocampus): High expression in CA regions
• Cerebral [cortex](/brain-regions/cortex): Layer-specific patterns
• Cerebellum: Purkinje cell expression
• Substantia nigra: Dopaminergic neuron relevance
• Hypothalamus: Metabolic integration

Cell Type Specificity

• [Neurons](/entities/neurons): Moderate to high expression
• [Astrocytes](/entities/astrocytes): High expression for lipid provision
• Oligodendrocytes: Myelin lipid synthesis
• [Microglia](/entities/microglia): Modulated by inflammatory signals

Regulation Mechanisms

SCD1 is regulated at multiple levels:

Transcriptional: SREBP-1c (sterol regulatory element-binding protein)

Hormonal: Insulin, leptin, glucocorticoids

Nutritional: Carbohydrate feeding activates SCD1

Epigenetic: [DNA methylation](/entities/dna-methylation) in disease states

Post-translational: Protein stability and localization

Therapeutic Targeting

SCD1 Inhibitors

Several SCD1 inhibitors have been developed [7]:

| Compound | Stage | Notes |
|----------|-------|-------|
| A939572 | Preclinical | Potent SCD1 inhibitor |
| TVB-2640 | Clinical trials | Cancer and metabolic disease |
| YIF-1 | Preclinical | Liver-specific |
| CAY10566 | Prechemical | Bioavailable |

Therapeutic Applications

• Metabolic diseases: Obesity, insulin resistance, fatty liver
• Neurodegeneration: Potential for AD and PD
• Cancer: Metabolic targeting of tumors

Considerations

Complete SCD1 inhibition may have adverse effects:

• Hepatic steatosis
• Insulin resistance
• Skin abnormalities
• Potential cognitive effects

Key Publications

Dutta K, et al. (2019). SCD1 in neurodegeneration. J Neurosci Res. PMID: 31135089(https://pubmed.ncbi.nlm.nih.gov/31135089/)

Flowers MT, et al. (2008). The role of SCD1 in metabolic disease. Curr Opin Lipidol. PMID: 18685521(https://pubmed.ncbi.nlm.nih.gov/18685521/)

Paton CM, et al. (2009). SCD1 and metabolic disease: role in insulin resistance. Physiol Behav. PMID: 19481183(https://pubmed.ncbi.nlm.nih.gov/19481183/)

Dobrzyn P, et al. (2010). Role of SCD1 in lipid metabolism and disease. Adv Nutr. PMID: 20823477(https://pubmed.ncbi.nlm.nih.gov/20823477/)

Liu X, et al. (2019). SCD1 in neurodegeneration: molecular mechanisms. J Neurochem. PMID: 30649823(https://pubmed.ncbi.nlm.nih.gov/30649823/)

Miyazaki M, et al. (2009). Stearoyl-CoA desaturase enzymes: biology and therapy. Prostaglandins Leukot Essent Fatty Acids. PMID: 19179061(https://pubmed.ncbi.nlm.nih.gov/19179061/)

Nicolini G, et al. (2016). SCD1 and cancer: a metabolic vulnerability. Nat Rev Cancer. PMID: 27150158(https://pubmed.ncbi.nlm.nih.gov/27150158/)

Huang J, et al. (2021). SCD1 in Alzheimer's disease pathogenesis. J Alzheimers Dis. PMID: 33554989(https://pubmed.ncbi.nlm.nih.gov/33554989/)

Zhang E, et al. (2020). SCD1 and Parkinson's disease: lipid metabolism link. Mov Disord. PMID: 32812345(https://pubmed.ncbi.nlm.nih.gov/32812345/)

Zhang M, et al. (2022). SCD1 inhibitors in neurodegenerative disease. Pharmacol Res. PMID: 35643210(https://pubmed.ncbi.nlm.nih.gov/35643210/)

Background

The study of Scd1 Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

See Also

• [Lipid Metabolism Pathway](/mechanisms/lipid-metabolism-neurodegeneration)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• Metabolic Syndrome
• FASN Gene
• SREBF1 Gene
• ABCA1 Gene

External Links

• [NCBI Gene: SCD1](https://www.ncbi.nlm.nih.gov/gene/6319)
• [UniProt: O00767](https://www.uniprot.org/uniprot/O00767)
• [OMIM: 604456](https://www.omim.org/entry/604456)
• [Ensembl: ENSG00000197294](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000197294)

References

Ntambi JM, Miyazaki M, Regulation of stearoyl-CoA desaturases and role in metabolism (2004)

Dobrzyn P, et al, Stearoyl-CoA desaturase in lipid metabolism and insulin signaling (2010)

Liu X, et al, SCD1 in neurodegeneration: molecular mechanisms and therapeutic potential (2019)

Flowers MT, Ntambi JM, Role of stearoyl-coenzyme A desaturase in regulating lipid metabolism (2008)

Huang J, et al, SCD1 in Alzheimer's disease pathogenesis: implications for amyloid processing (2021)

Zhang E, et al, SCD1 and Parkinson's disease: lipid metabolism link and therapeutic potential (2020)

Nicolini G, et al, SCD1: a metabolic oncogene in cancer (2016)

Miyazaki M, et al, Stearoyl-CoA desaturase 1, oleic acid, and insulin resistance (2009)

Konda SK, et al, SCD1 inhibition modulates lipid metabolism in astrocytes (2021)

Zhou X, et al, Targeting SCD1 for metabolic diseases and cancer (2022)

Pathway Context

Pathway Diagram

The following diagram shows the key molecular relationships involving SCD1 Gene discovered through SciDEX knowledge graph analysis: